@stockrock
Re "
Not sure if you addressed this elsewhere, but what do you think of the recent China deal and talk of similar CHF deals being done in Japan, Korea etc or even expanding the Tasly partnership to manufacture other MSCs
MSB have in recent times been able to capitalise on its IP through TiGenix and partnering with Tasly ... bolster its cash and funding through debt and cap raisings (@ 5% and 20% premiums)... what would it take to convert a non-holder like yourself to finally get your feet wet?"
I have been asked before about my longer term plans in relation to msb. I think this reply to
4Seasons still best reflects where I stand.
In contrast to the opinion of the noisiest of all of the posters on this group, I believe I have been quite consistent in most of my views. With chf, I was positive about Teva's involvement pre June 2016; it is quite easy to double-check - here's one from
April 2016 - see last paragraph.
As it turns out, Teva was not as committed as I thought but I stand by the view that it is quite likely, at some point, stem cells will have a significant role to play in the treatment of diseases. The aGVHD results demonstrate the potential, although I am still sticking to my view that the children's market is too small.
As for the recent Tasly announcement, I can see the details, it is okish. I suspect there is a long road ahead in China so imo it is, like many ventures before, a case of wait and see. I am looking forward to future reports on RA and CHF trials.
Re "
Out of interest are you the type to wait until positive quarterly cash flows, or would you consider an earlier entry?"
Simple answer, is "Conditionally, yes, an earlier entry is possible". What money I have is probably > 85% invested in boring blue-chip. In that area, I am looking almost entirely at free cash flow and explanations if things dip at all in that area. My less blue-chippy interest lies in lithium, sleep diagnostics, genetic technology (a small disaster for me) and a few other bits and bobs. I watch it all carefully and I am lucky I have a few people in my life who know more than me to advise here and there. For all that, it is not as interesting to me as discussing MSB (or even SPL).
The conditional around Mesoblast would be seeing a substantial partner agreeing terms in one or more of the major treatment areas (e.g. Celgene would have been great). I would also be wanting to know the target market size and get a clear understanding of trial results and the market challenges they face. MSB are addressing conditions that either have no alternatives, or the alternatives are grim. One of the more enlightened posters on this group occasionally mentions the word "juggernaut" in relation to MSB achieving success, that seems a reasonable summation.
I am entirely comfortable with the idea that such a circumstance would take the share price up from it's current position, but less risk often makes the extra cost worthwhile. My worst mistakes relate to investing FOMO, it is a curse and, like all people, I struggle to ignore it. If things go well and the risks were reduced then, as much as I could, I would then keep buying. much as most people would.
In summary, I do come across as negative about Mesoblast. In my defence, I think the negativity of my posts are in proportion to the absurdity or misleading nature of the post to which I am responding.
All the best to you too.
(20min delay)